Urinary peptide profiling to differentiate between minimal change disease and focal segmental glomerulosclerosis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Pérez, Vanessa ^a,b   Ibernón, Meritxell ^a   López, Dolores ^a   Pastor, María Cruz ^a   Navarro, Maruja ^a   Navarro Muñoz, Maribel ^a,b   Bonet, Josep ^a   Romero, Ramón ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; TAMM HORSFALL GLYCOPROTEIN;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; KIDNEY BIOPSY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMAL CHANGE GLOMERULONEPHRITIS; PEPTIDOMICS; PREDICTION; REPRODUCIBILITY; URINALYSIS;

ADULT; AGED; ALPHA 1-ANTITRYPSIN; BIOLOGICAL MARKERS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY DISEASES; MALE; NEPHROSIS, LIPOID; PEPTIDES; PROSPECTIVE STUDIES; URINARY TRACT;

EID: 84900451800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087731     Document Type: Article

References (37)

1. NationalKidneyFoundation (2012) KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 60: 850-886.
2. McGrogan A, Franssen CF, de Vries CS (2010) The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 26: 414-430.
3. Braden GL, Mulhern JG, O'Shea MH, Nash SV, Ucci AA Jr, et al. (2000) Changing incidence of glomerular diseases in adults. Am J Kidney Dis 35: 878-883. (Pubitemid 30238200)
4. Madaio MP (1990) Renal biopsy. Kidney Int 38: 529-543.
5. Eiro M, Katoh T, Watanabe T (2005) Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol 9: 40-45. (Pubitemid 40576883)
6. Corapi KM, Chen JL, Balk EM, Gordon CE (2012) Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis 60: 62-73.
7. Corwin HL, Schwartz MM, Lewis EJ (1988) The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol 8: 85-89.
8. Fogo AB (2003) Approach to renal biopsy. Am J Kidney Dis 42: 826-836.
9. Mak SK, Short CD, Mallick NP (1996) Long-term outcome of adult-onset minimal-change nephropathy. Nephrol Dial Transplant 11: 2192-2201. (Pubitemid 26385914)
10. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, et al. (2007) Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2: 445-453.
11. Drube J, Schiffer E, Mischak H, Kemper MJ, Neuhaus T, et al. (2009) Urinary proteome pattern in children with renal Fanconi syndrome. Nephrol Dial Transplant 24: 2161-2169.
12. Navarro-Munoz M, Ibernon M, Bonet J, Perez V, Pastor MC, et al. (2012) Uromodulin and alpha(1)-antitrypsin urinary peptide analysis to differentiate glomerular kidney diseases. Kidney Blood Press Res 35: 314-325.
13. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, et al. (2005) Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 67: 2313-2320. (Pubitemid 41623391)
14. Lapolla A, Seraglia R, Molin L, Williams K, Cosma C, et al. (2009) Low molecular weight proteins in urines from healthy subjects as well as diabetic, nephropathic and diabetic-nephropathic patients: a MALDI study. J Mass Spectrom 44: 419-425.
15. Good DM, Thongboonkerd V, Novak J, Bascands JL, Schanstra JP, et al. (2007) Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res 6: 4549-4555.
16. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, et al. (2004) Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 76: 1560-1570. (Pubitemid 38338398)
17. Baumann S, Ceglarek U, Fiedler GM, Lembcke J, Leichtle A, et al. (2005) Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 51: 973-980. (Pubitemid 40740877)
18. Zhang J, Zhou S, Li R, Cao T, Zheng H, et al. (2012) Magnetic bead-based salivary peptidome profiling for periodontal-orthodontic treatment. Proteome Sci 10: 63.
19. Perez V, Navarro-Munoz M, Mas S, Bayes B, Pastor MC, et al. (2011) Proteomic approach to the study of statin pleiotropy in kidney transplant patients. Pharmacology 87: 161-168.
20. Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, et al. (2005) Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 51: 2236-2244. (Pubitemid 41692565)
21. Perez V, Sanchez-Escuredo A, Lauzurica R, Bayes B, Navarro-Munoz M, et al. (2013) Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients. Eur J Pharmacol.
22. Perez V, Sanchez A, Bayes B, Navarro-Munoz M, Lauzurica R, et al. (2010) Effect of paricalcitol on the urinary peptidome of kidney transplant patients. Transplant Proc 42: 2924-2927.
23. Jimenez CR, Koel-Simmelink M, Pham TV, van der Voort L, Teunissen CE (2007) Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: Optimization of magnetic bead-based peptide capture and analysis of preanalytical variables. Proteomics Clin Appl 1: 1385-1392.
24. Taneja S, Ahmad I, Sen S, Kumar S, Arora R, et al. (2011) Plasma peptidome profiling of acute hepatitis E patients by MALDI-TOF/TOF. Proteome Sci 9: 5.
25. Zhang X, Leung SM, Morris CR, Shigenaga MK (2004) Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J Biomol Tech 15: 167-175.
26. Fiedler GM, Baumann S, Leichtle A, Oltmann A, Kase J, et al. (2007) Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 53: 421-428. (Pubitemid 46447938)
27. Surin B, Sachon E, Rougier JP, Steverlynck C, Garreau C, et al. (2012) LG3 fragment of endorepellin is a possible biomarker of severity in IgA nephropathy. Proteomics 13: 142-152.
28. Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, et al. (2007) Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 18: 913-922. (Pubitemid 46434508)
29. Candiano G, Musante L, Bruschi M, Petretto A, Santucci L, et al. (2006) Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J Am Soc Nephrol 17: 3139-3148. (Pubitemid 44707774)
30. Rindler MJ, Naik SS, Li N, Hoops TC, Peraldi MN (1990) Uromodulin (Tamm-Horsfall glycoprotein/uromucoid) is a phosphatidylinositol-linked membrane protein. J Biol Chem 265: 20784-20789. (Pubitemid 120014078)
31. Prajczer S, Heidenreich U, Pfaller W, Kotanko P, Lhotta K, et al. (2010) Evidence for a role of uromodulin in chronic kidney disease progression. Nephrol Dial Transplant 25: 1896-1903.
32. Wu J, Wang N, Wang J, Xie Y, Li Y, et al. (2010) Identification of a uromodulin fragment for diagnosis of IgA nephropathy. Rapid Commun Mass Spectrom 24: 1971-1978.
33. Lapolla A, Molin L, Sechi A, Cosma C, Ragazzi E, et al. (2009) A further investigation on a MALDI-based method for evaluation of markers of renal damage. J Mass Spectrom 44: 1754-1760.
34. Abboud RT, Ford GT, Chapman KR (2001) Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. Can Respir J 8: 81-88. (Pubitemid 32496355)
35. Society ATSER (2003) American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 168: 818-900.
36. Eriksson S, Carlson J, Velez R (1986) Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 314: 736-739. (Pubitemid 16124387)
37. Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, et al. (2010) Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 78: 296-302.